Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma

Inclusion Criteria:

• Patients ≥ 18 years

• histologically confirmed inoperable locally advanced, recurrent, or metastaticadenocarcinoma of the stomach or gastro-oesophageal junction;

• ECOG (Eastern Cooperative Oncology Group) performance status 0-2;

• adequate renal, hepatic, and hematologic function;

• measurable or nonmeasurable disease according to the Response Evaluation Criteria inSolid Tumors (RECIST). Patients with intraoperatively confirmed intraperitonealmetastases but without detectable disease in radiological studies were also eligible

Exclusion Criteria:

• HER2- positive tumors defined as either IHC 3+ or IHC 2+, the latter in combinationwith FISH+

• previous chemotherapy for metastatic or locally advanced disease

• surgery <3 weeks before the onset of the study treatment

• congestive heart failure

• significant dysphagia that would preclude oral administration of capecitabine

• concurrent malignant disease, except for adequately treated tumors with highlikelihood of being cured (e.g. basal cell carcinoma of the skin, cervical cancer)

• clinical evidence of brain metastases